Compass Therapeutics Inc (CMPX) concluded trading on Wednesday at a closing price of $1.86, with 24.15 million shares of worth about $44.93 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 95.36% during that period and on January 08, 2025 the price saw a gain of about 30.07%. Currently the company’s common shares owned by public are about 137.59M shares, out of which, 84.48M shares are available for trading.
Stock saw a price change of 28.28% in past 5 days and over the past one month there was a price change of 12.05%. Year-to-date (YTD), CMPX shares are showing a performance of 28.28% which increased to 2.76% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.76 but also hit the highest price of $2.34 during that period. The average intraday trading volume for Compass Therapeutics Inc shares is 477.29K. The stock is currently trading 22.53% above its 20-day simple moving average (SMA20), while that difference is up 17.87% for SMA50 and it goes to 26.56% higher than SMA200.
Compass Therapeutics Inc (NASDAQ: CMPX) currently have 137.59M outstanding shares and institutions hold larger chunk of about 39.10% of that.
The stock has a current market capitalization of $255.91M and its 3Y-monthly beta is at 0.76. It has posted earnings per share of -$0.36 in the same period. It has Quick Ratio of 31.84 while making debt-to-equity ratio of 0.05. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CMPX, volatility over the week remained 23.93% while standing at 11.98% over the month.
Stock’s fiscal year EPS is expected to drop by -6.06% while it is estimated to decrease by -13.59% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by D. Boral Capital on December 23, 2024 offering a Buy rating for the stock and assigned a target price of $32 to it. Coverage by Leerink Partners stated Compass Therapeutics Inc (CMPX) stock as a Market perform in their note to investors on November 15, 2024, suggesting a price target of $4 for the stock. On September 16, 2024, Ladenburg Thalmann Upgrade their recommendations, while on January 31, 2023, Jefferies Initiated their ratings for the stock with a price target of $8. Stock get a Buy rating from Stifel on January 27, 2023.